Conference Posters

October 2022
National Organization for Rare Diseases (NORD) Rare Diseases and Orphan Products Breakthrough Summit
The “Living with Chronic Neutropenia” Survey: Experiences and Preferences of People Living with Chronic Neutropenia

October 2022
The European Society for Immunodeficiencies (ESID)
Case Study: A Novel CXCR4 p.Ser346Profs*12 Variant in a Child With WHIM Syndrome

September 2022
North American Immuno-Hematology Clinical Education & Research (NICER) Symposium
Administration of Mavorixafor, an Orally Available CXCR4 Antagonist, Increases Total White Blood Cell, Neutrophil, Lymphocyte, and Monocyte Counts Across Different Disease States

September 2022
North American Immuno-Hematology Clinical Education & Research (NICER) Symposium
Characterization of Novel CXCR4 Variants to Support Expanded Genetic Testing for WHIM Syndrome Phenotypes  

June 2022
European Hematology Association (EHA) Annual Congress
Screening of Naturally Occurring CXCR4Variants for Identification of Novel Pathogenic Mutations for WHIM Syndrome

June 2022
European Hematology Association (EHA) Annual Congress
Mavorixafor Disrupts the Crosstalk Between Waldenström’s Macroglobulinemia Cells and the Bone Marrow Microenvironment Resulting in Enhanced Sensitivity to B-Cell–Targeted Therapies

June 2022
European Hematology Association (EHA) Annual Congress
Crispr/Cas9-Based Model of Heterozygous CXCR4WT/R334x Mutation to Study Cellular Phenotypes in WHIM Syndrome

April 2022
American Association for Cancer Research (AACR) Annual Meeting
Pre-Clinical Study of Mavorixafor plus BTKis

April 2022
Clinical Immunology Society (CIS) Annual Meeting
PATH4WARD: A Genetic Testing Program to Aid in Molecular Diagnosis of Congenital Neutropenia and Other Primary Immunodeficiencies Including WHIM Syndrome

April 2022
Clinical Immunology Society (CIS) Annual Meeting
4WHIM: Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients With WHIM Syndrome via a Global, Phase 3, Randomized, Placebo-Controlled Trial With Open-Label Extension

February 2022
American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
Effects of Mavorixafor on Functional Impairments Due to a Novel Missense CXCR4 Mutation in a Patient With WHIM Syndrome Phenotype

December 2021
63rd American Society of Hematology (ASH) Annual Meeting
Comprehensive in Vitro Characterization of CXCR4-WHIM variants to Decipher Genotype–Phenotype Correlations in WHIM Syndrome

December 2021
63rd American Society of Hematology (ASH) Annual Meeting
Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States

December 2021
63rd American Society of Hematology (ASH) Annual Meeting
Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström’s Macroglobulinemia with MYD88 and CXCR4 Mutations

December 2021
63rd American Society of Hematology (ASH) Annual Meeting
Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients With WHIM Syndrome: Results From the Long-Term Extension of theOpen-Label Phase 2 Study

October 2021
National Organization for Rare Disorders (NORD) Rare Disease and Orphan Products Breakthrough Summit
Living with WHIM Syndrome The Patient Perspective

June 2021
26ᵗʰ European Hematology Association (EHA) Annual Congress
Preliminary Clinical Data From a Phase 1b Study of Mavorixafor and Ibrutinib in Patients With Waldenström’s Macroglobulinemia With MYD88 and CXCR4 Mutations

June 2020
25ᵗʰ European Hematology Association (EHA) Annual Congress
Oral CXCR4 Antagonist Mavorixafor Treatment in WHIM Syndrome: Results of an Open Label Phase 2 Study With Long-Term extension

September 2019
European Society for Medical Oncology (ESMO) 2019 Congress
Safety and Efficacy of the Oral CXCR4 Inhibitor X4P-001 + Axitinib in Advanced Renal Cell Carcinoma Patients: An Analysis of Subgroup Responses by Prior Treatment

December 2018
60th Annual Meeting of the American Society of Hematology
Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome

November 2018
The Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Tumor Inflammatory Status in the Microenvironment of Melanoma

October 2018
European Society for Medical Oncology (ESMO) 2018 Congress
Combination Therapy with the CXCR4 Inhibitor X4P-001 and Nivolumab Demonstrates Preliminary Anti-tumor Activity in RCC Patients that are Unresponsive to Nivolumab Alone

National Organization for Rare Disorders (NORD) Rare Disease and Orphan Products Breakthrough Summit
Review of Case Report Literature Highlights that WHIM Syndrome has Serious Long-term Outcomes Beyond Warts and Infections

First WHIM Genetic Screening Study Developed Through a Collaborative Effort Among Academia, Patient Foundation, and Sponsors

Emerging Picture of Morbidity in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

June 2018
23rd Congress of the European Hematology Association (EHA)
Phase 2 Study of X4P-001: A Targeted Oral Therapy for Patients with WHIM Syndrome

2018 American Society of Clinical Oncology (ASCO) Annual Meeting
A Phase 1/2 Study Evaluating the Efficacy and Safety of the Oral CXCR4 Inhibitor X4P-001 in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma

May 2018
16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy

April 2018
2018 American Association for Cancer Research (AACR) Annual Meeting
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Enhances Immune Cell Infiltration and Activation in the Tumor Microenvironment of Melanoma

CXCR4 Inhibition Modulates Tumor Microenvironment and Robustly Inhibits Growth of B16-OVA Melanoma

December 2017
59th Annual Meeting of the American Society for Hematology (ASH)
X4P-001: A Novel Molecularly-Targeted Oral Therapy for WHIM Syndrome

November 2017
Society for Immunotherapy of Cancer (SITC) Annual Meeting
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T Cell Infiltration in Human Metastatic Melanoma

Efficacy and Mechanism of Action of CXCR4 Inhibition in B16 OVA Melanoma Model

October 2017
2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
A Phase 1 Dose Finding Study of X4P-001 (An Oral CXCR4 Inhibitor) and Axitinib in Patients with Advanced Renal Cell Carcinoma

September 2017
European Society of Medical Oncology 2017 Congress
A Phase 1 Dose Finding Study of X4P-001 (An Oral CXCR4 Inhibitor) and Axitinib in Patients with Advanced Renal Cell Carcinoma

November 2016
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Anti-tumor activity of X4P-001 in RCC with VEGF inhibitor

April 2016
American Association of Cancer Research (AACR) Annual Meeting 2016
MDSC Trafficking and Function in RCC by CXCR4 in the Presence of a VEGF-R Antagonist is Dependent on HIF-2α Express

 

X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.

Continue